Display options
Cite
Muniz VP, Askeland RW, Zhang X, et al. RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes Cancer. 2013;4(7):273-84doi: 10.1177/1947601913501074.
Muniz, V. P., Askeland, R. W., Zhang, X., Reed, S. M., Tompkins, V. S., Hagen, J., McDowell, B. D., Button, A., Smith, B. J., Weydert, J. A., Mezhir, J. J., & Quelle, D. E. (2013). RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes & cancer, 4(7), 273-84. https://doi.org/10.1177/1947601913501074
Muniz, Viviane P, et al. "RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients." Genes & cancer vol. 4,7 (2013): 273-84. doi: https://doi.org/10.1177/1947601913501074
Muniz VP, Askeland RW, Zhang X, Reed SM, Tompkins VS, Hagen J, McDowell BD, Button A, Smith BJ, Weydert JA, Mezhir JJ, Quelle DE. RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes Cancer. 2013 Jul;4(7):273-84. doi: 10.1177/1947601913501074. PMID: 24167655; PMCID: PMC3807645.
Copy Download .nbib Format: NLM
Share it on

Genes Cancer. 2013 Jul;4(7):273-84. doi: 10.1177/1947601913501074.

RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.

Genes & cancer

Viviane P Muniz, Ryan W Askeland, Xuefeng Zhang, Sara M Reed, Van S Tompkins, Jussara Hagen, Bradley D McDowell, Anna Button, Brian J Smith, Jamie A Weydert, James J Mezhir, Dawn E Quelle

Affiliations

  1. The Molecular and Cellular Biology Graduate Program, University of Iowa, Iowa City, IA, USA.

PMID: 24167655 PMCID: PMC3807645 DOI: 10.1177/1947601913501074

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by early recurrence following pancreatectomy, rapid progression, and chemoresistance. Novel prognostic and predictive biomarkers are urgently needed to both stratify patients for clinical trials and select patients for adjuvant therapy regimens. This study sought to determine the biological significance of RABL6A (RAB, member RAS oncogene family-like protein 6 isoform A), a novel pancreatic protein, in PDAC. Analyses of RABL6A protein expression in PDAC specimens from 73 patients who underwent pancreatic resection showed that RABL6A levels are altered in 74% of tumors relative to adjacent benign ductal epithelium. Undetectable RABL6A expression, found in 7% (5/73) of patients, correlated with improved overall survival (range 41 to 118 months with 3/5 patients still living), while patients with RABL6A expression had a worse outcome (range 3.3 to 100 months, median survival 20.3 months) (P = 0.0134). In agreement with those findings, RABL6A expression was increased in pancreatic cancer cell lines compared to normal pancreatic epithelial cells, and its knockdown inhibited pancreatic cancer cell proliferation and induced apoptosis. Moreover, RABL6A depletion selectively sensitized cells to oxaliplatin-induced arrest and death. This work reveals that RABL6A promotes the proliferation, survival, and oxaliplatin resistance of PDAC cells, whereas its loss is associated with extended survival in patients with resected PDAC. Such data suggest RABL6A is a novel biomarker of PDAC and potential target for anticancer therapy.

Keywords: ARF; RABL6A; chemoresistance; oxaliplatin; pancreatic ductal adenocarcinoma

References

  1. Am J Pathol. 2003 Apr;162(4):1151-62 - PubMed
  2. Chem Biol Interact. 2009 Dec 10;182(2-3):173-82 - PubMed
  3. Mol Cell Biol. 2005 Feb;25(4):1258-71 - PubMed
  4. Mod Pathol. 2010 Jan;23(1):98-104 - PubMed
  5. Ann Surg. 2010 Sep;252(3):499-505; discussion 505-6 - PubMed
  6. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 - PubMed
  7. Nat Rev Cancer. 2009 Jan;9(1):28-39 - PubMed
  8. Transl Oncol. 2008 Mar;1(1):36-43 - PubMed
  9. Cell. 1995 Dec 15;83(6):993-1000 - PubMed
  10. Oncology. 2011;80(5-6):301-6 - PubMed
  11. Clin Cancer Res. 2006 Apr 15;12(8):2492-7 - PubMed
  12. Nature. 2012 Mar 28;483(7391):603-7 - PubMed
  13. Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3 - PubMed
  14. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  15. Nat Rev Cancer. 2002 Dec;2(12):897-909 - PubMed
  16. J Biol Chem. 2011 Apr 8;286(14):12157-65 - PubMed
  17. Br J Cancer. 2007 May 7;96(9):1358-67 - PubMed
  18. Cancer Res. 2009 Jun 1;69(11):4567-72 - PubMed
  19. EMBO J. 2006 Jun 7;25(11):2584-95 - PubMed
  20. Br J Cancer. 2008 Sep 2;99(5):760-7 - PubMed
  21. Cancer Sci. 2005 Jul;96(7):387-93 - PubMed
  22. N Engl J Med. 2011 May 12;364(19):1817-25 - PubMed
  23. Nat Rev Cancer. 2006 Sep;6(9):663-73 - PubMed
  24. World J Gastroenterol. 2012 Feb 28;18(8):736-45 - PubMed
  25. Nature. 2012 Apr 29;486(7402):266-70 - PubMed
  26. J Pharmacol Exp Ther. 2008 Dec;327(3):746-59 - PubMed
  27. Nucleic Acids Res. 2001 May 1;29(9):e45 - PubMed
  28. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  29. Anticancer Res. 2010 Jul;30(7):2531-8 - PubMed
  30. Cancer Res. 2012 May 15;72(10):2554-64 - PubMed
  31. J Clin Oncol. 2011 Oct 1;29(28):3727-9 - PubMed
  32. Anticancer Res. 2006 May-Jun;26(3A):2093-9 - PubMed
  33. Nature. 2012 Mar 28;483(7391):570-5 - PubMed
  34. Pharm Res. 2010 Jun;27(6):1146-58 - PubMed
  35. N Engl J Med. 2010 Apr 29;362(17):1605-17 - PubMed
  36. Cell Cycle. 2006 Mar;5(6):641-6 - PubMed
  37. Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92 - PubMed
  38. Ann Surg Oncol. 2006 Jul;13(7):933-9 - PubMed
  39. J Biol Chem. 2007 Dec 28;282(52):37640-9 - PubMed
  40. Expert Opin Drug Deliv. 2010 Mar;7(3):273-84 - PubMed
  41. Curr Cancer Drug Targets. 2010 Nov;10(7):660-9 - PubMed
  42. JAMA. 2007 Jan 17;297(3):267-77 - PubMed
  43. Clin Cancer Res. 2011 May 15;17(10):3316-31 - PubMed
  44. J Biol Chem. 2009 Jul 3;284(27):18129-42 - PubMed

Publication Types

Grant support